利多卡因输注治疗难治性三叉神经痛:回顾性病例系列与系统综述
首次静脉注射后16例(80%)疼痛获药物充分控制,9例(45%)疼痛减轻持续超过6个月,无治疗相关显著不良事件。结论认为利多卡因输注联合持续药物治疗对难治性加重期三叉神经痛安全且改善疼痛控制。
要点
- 首次静脉利多卡因后80%患者疼痛获药物充分控制。
- 45%患者疼痛减轻持续超过6个月,无显著不良事件。
- 利多卡因输注可作为难治性三叉神经痛的辅助治疗。
核心结论
- 利多卡因输注治疗难治性加重期三叉神经痛安全,联合持续药物治疗可改善疼痛控制。
主要发现
- 首次静脉利多卡因注射后16例(80%)达到疗效评分III,即疼痛经药物充分控制。
- 1例达到BNI评分II,3例(15%)对治疗无反应。
- 9例(45%)疼痛强度减轻持续超过6个月,6例(30%)持续不足3个月,5例(25%)持续3至6个月。
- 未发生治疗相关显著不良事件。
临床怎么用
- 对标准治疗无效的难治性三叉神经痛患者,可考虑静脉利多卡因输注作为辅助治疗以改善疼痛控制。
局限性
- 回顾性病例系列样本量小(20例),证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trigeminal neuralgia classically manifests with intense facial pain. When the condition is unresponsive to standard treatment, it is referred to as refractory trigeminal neuralgia. AIMS AND OBJECTIVES: The study aimed to investigate the effectiveness, duration of pain relief and safety profile of intravenous Lidocaine in managing this debilitating condition. MATERIALS AND METHODS: A retrospective case series in a UK tertiary neurosurgery centre studied twenty trigeminal neuralgia patients who underwent Lidocaine infusion from January 2016 to December 2022. A systematic review of the literature was also undertaken. RESULTS: After the first intravenous Lidocaine injection, 16 patients (80%) achieved an efficacy score of III, i.e. they reported pain that had become adequately controlled with their medications. In addition, one patient achieved a BNI score of II and three patients (15%) did not respond to treatment. In addition, nine patients (45%) reported reduced pain intensity for more than six months, six patients (30%) for less than three months, and five patients (25%) for three to six months. There were no treatment-related significant adverse events. CONCLUSION: Lidocaine infusion therapy for refractory worsening trigeminal neuralgia is safe and improved pain control when combined with ongoing medical therapy.
引用
- Mohamed MW, Irem-Oko F, Sheikh A, et al. Lidocaine infusion for the treatment of intractable trigeminal neuralgia: retrospective case series and systematic review. Acta Neurochir (Wien). 2025. PMID: 41021111. doi:10.1007/s00701-025-06672-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。